Transient Induction of E-Selectin Expression Following TNFα-Based Isolated Limb Perfusion in Melanoma and Sarcoma Patients Is Not Tumor Specific

Peet T. G. A. Nooijen, *Alexander M. M. Eggermont, Marcel M. Verbeek, Lia Schalkwijk, †Wim A. Buurman, Robert M. W. de Waal, and Dirk J. Ruiter

Department of Pathology, University Hospital Nijmegen, Nijmegen; and Departments of Surgery, *Dr. Daniel den Hoed Cancer Centre, Rotterdam, and †University Hospital Maastricht, Maastricht, The Netherlands

Summary: Endothelial injury of the tumor microvasculature after isolated limb perfusion (ILP) with TNF-α and melphalan is considered to play an important role in the pathogenesis of tumor necrosis. It is thought to follow endothelial cell activation and subsequent attraction of polymorphonuclear cells (PMNs). The observed selectivity for the tumor could be due to preferential overexpression of cell-adhesion molecules by the tumor vasculature. We tested this proposition by analyzing sequential biopsies from both tumor and normal distant skin, taken from melanoma and sarcoma patients before ILP and at 30 min and 24 h after ILP. Histopathologically confirmed complete response was observed in six of seven melanoma patients, 1–8 months after ILP. By using immunohistochemistry on the light- and electron-microscopic level, the expression patterns of intercellular adhesion molecules-1 (ICAM-1), E-selectin (ELAM-1), VCAM-1, and PECAM-1 were examined. In addition, the results were compared with the effects on HUVECs (human umbilical vein endothelial cells) in vitro of transient exposure of the agents used during ILP. ICAM-1 and PECAM-1 were constitutively expressed on vascular endothelial cells, both in normal tissues and in the tumor lesions. In biopsies taken 30 min after termination of the perfusion, a moderate induction of E-selectin expression on the vascular endothelium in the tumors and a marked expression on the vasculature in the perfused normal skin were observed. It decreased within 24 h after perfusion in both normal skin and in the tumor. The upregulation of E-selectin was accompanied neither by an influx of neutrophils nor by hemorrhagic necrosis. There were no drastic changes in the expression of VCAM-1, ICAM-1, or PECAM-1. These findings imply that the upregulation of E-selectin after ILP is not restricted to the tumor microvasculature and that, therefore, these microvascular events seem not to be the decisive pathomechanism responsible for tumor regression. Key Words: Melanoma—Sarcoma—TNF-α—Melphalan—Isolated limb perfusion.
of TNF-α in a closed compartment with acceptable side effects. The protocol used in our center involved a triple-drug regimen, based on the reported synergism of TNF-α with melphalan and interferon-γ (IFN-γ) supplemented with mild hyperthermia. In melanoma-in-transit metastasis (stage IIIA,B) a 90% complete response (CR) was obtained compared with ~40% CR rate after ILP with melphalan alone (5), a regimen cited usually in the literature. In irresectable soft-tissue sarcoma, this protocol was found to yield 50% CR with 87.5% limb salvage, because most tumors became resectable (6,7). The Department of Surgery, Dr. Daniël den Hoed Cancer Center, Rotterdam, The Netherlands, participated in a clinical trial to compare this triple-drug regimen with a double-drug regimen with TNF-α and melphalan. The double-drug treatment was used in 16 of 17 patients analyzed in this study.

Angiographic analysis performed 1 week to 10 days after ILP showed a dramatic diminishment of the tumor-associated vasculature, leaving the normal small vessels in the limb intact, including small vessels in close proximity to the tumor (8). Morphologic and immunohistochemical analysis of biopsies of melanoma and soft-tissue sarcoma lesions after ILP with the triple-drug regimen suggested that the tumor microvasculature is an important target for ILP. We and others showed previously that events like Von Willebrand factor (VWF) release, platelet aggregation, and congestion concentrated on the tumor vasculature, leaving the normal tissues largely unaffected (9,10). Moreover, Renard et al. (9) observed E-selectin and VCAM-1 expressed by the tumor vascular bed. In the non-involved tissues, expression should be largely unaltered. How­
However, a comparison with unexposed and exposed normal skin without tumor involvement was not made.

In our study, we challenged this proposed selectivity by analyzing sequential biopsies from both tumor lesions and normal distant skin from melanoma and sarcoma patients with extremity lesions. Biopsies were taken before ILP and 30 min and 24 h after termination of ILP with the double-drug regimen. We determined the expression patterns of the cellular adhesion molecules ICAM-1, E-selectin (ELAM-1), VCAM-1, and PECAM-1 (CD31) by immunohistochemical analysis on the light-microscopic (LM) and electron-microscopic (EM) level. In addition, the results were compared with in vitro (12) expression patterns of cultured HUVECs (human umbilical vein endothelial cells) to be able to delineate possible synergistic effects of TNF-α and melphalan.

Patients and Treatment Schedule

Specifications of the patient characteristics and biopsy samples are given in Table 1.

Seventeen patients who entered the ILP protocol in the Dr. Daniël den Hoed Cancer Canter, Rotterdam, The Netherlands, during the period between December 1993 and July 1994, were included in the study. Pertinent details about the inclusion criteria, types of drugs, and treatment schedule used were described earlier (5,6,8). ILP consisted on a 1.5-h perfusion with a total amount of 2–4 mg TNF-α in combination with melphalan, either 10 mg/L of perfused lower limb or 13 mg/L for the upper limb at mild hyperthermia (40°C). Sixteen patients were treated as follows. At time zero, TNF-α was injected as a bolus into the arterial line. Melphalan was administered 30 min later. One patient received 0.2 mg IFN-γ s.c. on 2 subsequent days before ILP. The ILP consisted of 0.2 mg IFN-γ, 4 mg TNF-α and melphalan, 10 mg/L in the perfused lower limb. In all patients, the limb was washed twice with 1 L of haemacell and 1 L of 6% dextran 70 (Macrodex; Pharmacia, Uppsala, Sweden) at the end of ILP. Radioiodinated human serum albumin was added to the perfusate to monitor potential leakage of the drugs into the systemic circulation. Perioperatively, dopamine was administered at 2 μg/kg/min by continuous infusion, usually for several hours up to 48 h. Fluid loading was applied before releasing the tourniquet at the end of the washing period.
E-SELECTIN EXPRESSION

TABLE 1. Patient characteristics and specification of biopsy samples

<table>
<thead>
<tr>
<th>Patient</th>
<th>Diagnosis</th>
<th>Normal skin (Number of biopsies)</th>
<th>Tumor (Number of biopsies)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Before ILP</td>
<td>30 min after ILP</td>
</tr>
<tr>
<td>1</td>
<td>Melanoma</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>Melanoma</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>Melanoma</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>Melanoma</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>5</td>
<td>Melanoma</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>6</td>
<td>Melanoma</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>7</td>
<td>Melanoma</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>8</td>
<td>Clear-cell sarcoma</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>9</td>
<td>Clear-cell sarcoma</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>10</td>
<td>Clear-cell sarcoma</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>11</td>
<td>Malignant fibrous histiocytoma</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>12</td>
<td>Synoviosarcoma</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>13</td>
<td>Malignant fibrous histiocytoma</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>14</td>
<td>Synoviosarcoma</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>15</td>
<td>Hemangioepithelioma</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>16</td>
<td>Epitheloid cell sarcoma</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>17</td>
<td>Lymphangiosarcoma</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

ILP, isolated limb perfusion.
* Material for immunoelectron microscopic analysis also was taken.

Oral informed consent to take sequential biopsies from normal skin of the involved extremity and the tumor lesions was obtained from the patients. Excision biopsy of normal skin was taken at least 15 cm outside the melanoma or sarcoma lesion in areas without macroscopic signs of disease. In total, 137 biopsies from 17 patients (excision and punch biopsies from melanoma patients and Trucut needle biopsies from sarcoma patients). From six patients samples from both normal skin and tumor tissue before, 30 min after, and 24 h after termination of ILP were taken and prepared for immunoelectron microscopy (IEM).

The responses to the ILP treatment—CR, partial response (PR), no change (NC), and progressive disease (PD)—were assessed by standardized criteria (13). In the melanoma patients, the response was histologically confirmed by a biopsy 1 to 8 months after perfusion. In sarcoma patients who underwent a resection or residual mass, extensive histologic examination of the resected specimen was performed. Six of seven melanoma patients had a CR to the treatment, whereas one had a PR. All sarcoma patients showed tumor softening and necrosis. One sarcoma patient had a CR with 100% necrosis, whereas nine of 10 had a PR.

Immunohistochemistry

Cryostat sections (4 μm) of normal skin, melanoma, and sarcoma lesions after ILP were air-dried overnight at room temperature (RT), fixed in acetone for 10 min, again air-dried and incubated with the primary antibody for 60 min. The following antibodies were used: PAL-E, recognizing endothelial cells (14,15) (our laboratory, undiluted supernatant); KH 58.01 POS, recognizing RaHuVWF (Von Willebrand factor; 1:400); CL203, recognizing ICAM-1 (16) (CD54 1:800; kindly provided by Dr. S. Ferrone); ENA-1, recognizing E-selectin (17), (CD62e 1:20; kindly provided by Dr. W. Buurman); 1G11, recognizing VCAM-1 (18) (CD106 1:20; Immunotech); BBA7, recognizing PECAM (19) (CD31 1:5000; British Biotechnology). Subsequently, sections were incubated for 30 min with peroxidase-labeled rabbit anti-mouse antibodies (Dako, 1:100) or with the ABC detection kit, according to the manufacturer's description (Vector, Burlingame, CA, U.S.A.). Each incubation was followed by extensive washing in phosphate-buffered saline (PBS). Peroxidase activity was visualized by incubation with the chromogen 3-amino-9-ethylcarbazole for 10 min. Sections were counterstained with Harris hematoxylin and mounted with Kaiser's glycerin. The whole procedure was performed at RT. Secondary antibodies were tested for cross-reactivity by omitting the primary antibody, and positive controls were performed by staining frozen sections of skin affected with acute or chronic inflammation.

The staining intensity of the endothelium and tumor cells was scored as negative (−), weak (+),
dull (+), moderate (++) or marked (+++). The proportion of vascular cross-sections stained for either antibody was estimated as a percentage of the total number of PAL-E-positive vascular cross-sections in the slide and scored in one of the following categories: 0-5%, 6-25%, 26-50%, 51-75%, and 76-100%. All slides were read by two independent observers. In case of disagreement, consensus could be reached by joint reexamination.

Enzymehistochemical detection of chloroacetateesterase for the localization of neutrophils and mast cells was performed by a standard method (20).

Immunoelectron Microscopy

A pre-embedding immunoperoxidase technique was used to demonstrate the precise cellular localization and subcellular distribution of the staining with the mAbs. Tissue specimens from normal skin and tumor were fixed for 4 h at RT in freshly prepared 2% paraformaldehyde in Sörensen's phosphate buffer (pH 7.4). After washing for 1 h in PBS at RT and for 45-60 min in 2.3 M sucrose solution, the tissue was snap-frozen in liquid nitrogen and stored at —196°C. Cryosections (30 μm) were washed in PBS at RT for 1.5 h. The sections were then developed for 8-10 min with the primary antibody at 4°C diluted in a PBG buffer (PBS + 0.5% BSA + 0.1% gelatin, pH 7.4) by using a rotary shaker. After washing in PBS for 1.5 h, the sections were incubated with a peroxidase-conjugated secondary antibody at the appropriate dilution in PGB for 1.5 h at RT.

Control sections were incubated with the secondary antibody alone. After extensive washing in PBS for 1.5 h at RT, the sections were incubated in a 5 mg/ml diaminobenzidine (DAB; Sigma, St. Louis, MO, U.S.A.) solution in PBS, containing 3 mg/ml ammonium-nickel-sulfate-hexahydrate. The sections were then developed for 8-10 min in the same solution containing 0.01% H₂O₂. The reaction was terminated by rinsing with tap water. Sections were postfixixed with 1% osmium tetroxide for 5 min at RT, dehydrated, and embedded in Epon 812. Sections (1 μm) were stained with toluidine blue and examined light microscopically. Ultrathin sections were contrasted for 1 minute with 3% uranylacetate and examined on a JEOL 1200 EX/II electron microscope (Tokyo, Japan) at 40 kV.

ELISA

An enzyme-linked immunosorbent assay (ELISA) on cultured HUVECs was performed to detect E-selectin, ICAM-1, or VCAM-1 expression, as described previously (21). HUVECs were seeded in gelatin-coated 96-well microtiter plates (Costar, Cambridge, MA, U.S.A.) at a density of 2 × 10⁴ cells/well and allowed to grow to confluence in the appropriate medium for 3 days. Subsequently the cells were incubated with 10 μg/ml TNF-α (gift from Boehringer Ingelheim) or melphalan, 40 μg/ml, or perfusate, obtained during ILP and containing the actually used dose of TNF-α and melphalan, for 1 h. After extensive washing, cells were incubated in the culture medium again. After various intervals, cells were washed with EMEM (Eagle’s minimal essential medium, Biowhittaker, Belgium) and fixed with 0.025% glutaraldehyde in PBS for 10 min at RT. The wells were incubated with 1% gelatin in PBS for 30 min at 37°C to prevent nonspecific binding of antibodies. After washing with PBS, the wells were successively incubated for 30 min at 37°C with the primary antibodies and with peroxidase-labeled rabbit anti-mouse immunoglobulin (diluted 1:500 in PBS, containing 3 mg/ml diaminobenzidine (DAB; Sigma) in 50 mM phosphate buffer (pH 6.0) with 0.025% H₂O₂. The reaction was measured after 30 min by reading the optical density (OD) at 450 nm in a Titertek ELISA plate reader (Flow Laboratories, Irvine, Scotland).

RESULTS

Immunohistochemical Analysis

The results in this section are presented per individual adhesion molecule; staining intensity is expressed as described in the Materials and Methods section, followed by the percentage of positively stained blood vessels (100%, all PAL-E-stained vessels).

PECAM-1 Expression

In frozen sections of normal skin before ILP, marked PECAM-1 expression was detectable on the endothelial cells of venules, arterioles, and large vessels (+++ , 76-100%). The PAL-E-negative lymphatic endothelium also was positively stained with dull intensity (+). Melanoma and sarcoma cells did not stain. Vascular endothelial cells in either the melanoma or sarcoma lesions were markedly stained (++++ , 76–100%). The staining patterns in normal skin and in the tumor lesions were
not altered, both at 30 min and at 24 h after ILP (Figs. 1 and 3C). The melanoma and sarcoma cells remained unstained. IEM showed that the majority of the blood vessels were intensely labeled by the anti-PECAM-1 antibody at the luminal and abluminal side of the endothelium. Parts of the pinocytotic vesicles, mainly at the luminal side, were positively stained. No other part of the microvasculature showed PECAM-1 positivity (Fig. 3D).

**ICAM-1 Expression**

Before ILP, ICAM-1 was constitutively expressed in frozen sections of normal skin on vascular endothelial cells (+, 51–75%) and on dermal dendritic cells with dull staining intensity (+). The tumor vascular endothelium stained (+, 51–75%) in the melanoma and sarcoma lesions before ILP. In all melanoma lesions, tumor cells and stroma cells (+, 51–75%) were stained. Thirty minutes after termination of ILP, the staining intensity on the endothelial and dermal dendritic cells increased (from + to + +), both in normal skin and in the melanoma and sarcoma lesions. The percentage of the vessels stained remained unchanged (Fig. 5E). The staining of tumor cells and stromal cells remained unchanged. At 24 h after ILP, the staining intensity was decreased to the level observed before ILP (+, 51–75%), both in normal skin and in the tumor lesions (Figs. 1 and 3E). IEM analysis showed a marked ICAM-1 staining of the luminal side of endothelial cells. Sparsely pinocytotic vesicles were stained. No other part of the microvascular wall showed ICAM-1 staining (Fig. 3F).

**E-Selectin Expression**

In normal skin before ILP, the external sheath of the hair follicles markedly stained (+ + +), in contrast to the unstained vascular endothelial cells. Whether this staining could be considered specific or nonspecific was not known. Melanoma and sarcoma cells did not stain. The tumor vascular endothelium showed a weak staining (±, 5%) at the periphery of the tumor in two (of seven) melanomas and two (of 10) sarcoma lesions; in the remaining biopsies, the vascular endothelium did not stain. However, 30 min after termination of ILP, a high percentage (76–100%) of the vascular endothelium in normal distant skin and in skin adjacent to melanoma lesions stained with moderate to marked intensity (+ +/+ + +) (Figs. 1, 2A and B, 3A, and 6A).

**FIG. 1.** Staining patterns of endothelial cell adhesion molecules in normal adjacent skin and tumor tissue. Right bars, normal skin; left bars, tumor tissue. The length of each bar represents the percentage of vascular cross-sections stained, estimated as a percentage of the total number of PAL-E positive vascular cross-sections. The pattern of each bar corresponds to the intensity as follows: no shading, ± to +; light shading, ++; and dark shading, +++.
The endothelial cells near the area examined in the dermis, with low intensity of the vasculature staining (9–25%), showed a slightly positive background. With the exception of two drops of vaccine, no lesions before TP were negative for VCAM-1, while endothelial cells in normal skin and L-PP showed a positive reaction. VCAM-1 expression

The presence of endothelial cells was assessed by staining. The melanoma and sarcomas had lost their staining. The melanoma and sarcomas

The normal skin and melanoma and sarcomas lesions in iliac inguinal lymph nodes (Fig. 1) showed a positive reaction. No lesions before TP were negative for VCAM-1, suggesting that the melanoma expression of FP was not. In contrast, only a small fraction of the

**Fig. 2** Immunostaining for F-actin expression, b: Immunostaining for F-actin in a F-actin-positive lymph node, c: Immunostaining for F-actin in a positive lymph node, d: Immunostaining for F-actin in a negative lymph node. The lymph nodes are from melanoma.

**Fig. 3** Immunostaining for TNF-α in a lymph node, b: Immunostaining for TNF-α in a lymph node, c: Immunostaining for TNF-α in a lymph node, d: Immunostaining for TNF-α in a lymph node. The lymph nodes are from melanoma.

**Fig. 4** Immunostaining for IFN-γ in a lymph node, b: Immunostaining for IFN-γ in a lymph node, c: Immunostaining for IFN-γ in a lymph node, d: Immunostaining for IFN-γ in a lymph node. The lymph nodes are from melanoma.

**Fig. 5** Immunostaining for IL-1β in a lymph node, b: Immunostaining for IL-1β in a lymph node, c: Immunostaining for IL-1β in a lymph node, d: Immunostaining for IL-1β in a lymph node. The lymph nodes are from melanoma.
FIG. 3. Immunohistochemical and immunoelectron microscopic analysis of the expression of adhesion molecules in biopsies of isolated limb perfusion (ILP)-treated skin. Asterisks indicate lymph vessels. A: Immunostaining for E-selectin on a frozen section of normal skin, 30 min after perfusion with TNF-α and melphalan (e, epidermis; d, dermis). B: Immunoelectron microscopy. E-selectin is expressed on the luminal and abluminal side (diffuse) of the endothelium of a blood vessel in the dermis of normal skin, 30 min after perfusion with TNF-α and melphalan (E, endothelial cell). C: PECAM-1 immunostaining on a frozen section of normal skin, 30 min after perfusion with TNF-α and melphalan. D: Immunoelectron microscopy. PECAM-1 is expressed on the luminal and abluminal side of the endothelium of a blood vessel in the dermis of normal skin, 30 min after perfusion with TNF-α and melphalan (E, endothelial cell). E: ICAM-1 immunostaining on a frozen section of normal skin, 30 min after perfusion with TNF-α and melphalan. F: Immunoelectron microscopy. ICAM-1 is expressed on the luminal side of a blood vessel in the dermis of normal skin, 30 min after perfusion with TNF-α and melphalan (E, endothelial cell).
FIG. 4. The effects of a pulse of TNF-α (A, D, G), melphalan (B, E, H), and perfusate (C, F, I) on the expression of E-selectin (A, B, C), ICAM-1 (D, E, F), and VCAM-1 (G, H, I) by cultured HUVECs. The vertical axis represents arbitrary extinction units, read at 450 nm. One of four representative experiments is shown.

Melanoma and sarcoma cells did not stain. Thirty minutes after termination of ILP, the staining pattern was unchanged both in normal skin and in the melanoma and sarcoma lesions (Fig. 1). By IEM analysis, we did not observe VCAM-1 staining of the cutaneous microvasculature.

In Vitro Experiments

Although the use of cultured cells may have limited value in predicting or explaining in vivo mechanisms, we made an attempt to delineate possible synergistic effects of TNF-α and melphalan on the expression patterns of E-selectin, ICAM-1, and VCAM-1 on cultured HUVECs. To mimic the clinical situation most closely, the exposure of HUVECs to TNF-α, melphalan, and perfusate was limited to 1 h. The drug regimen used in vitro was similar to that used in vivo, which is based on the reported synergism of TNF-α with chemotherapy. Exposure of HUVECs to a pulse of TNF-α, 10 μg/ml for 1 h, resulted in a marked upregulation of E-selectin and ICAM-1 expression (Fig. 4A and D). E-selectin expression reached a maximum after 4 h and decreased within 24 h. ICAM-1 expression reached a maximum after 24 h. The VCAM-1 expression did not differ significantly from control levels (Fig. 4G).

Exposure of HUVECs to a pulse of melphalan, 40 μg for 1 h, did not result in a significant upregulation of E-selectin and VCAM-1 (Fig. 4B and H). Repeated experiments did not reveal a significant pattern of induction of ICAM-1 expression as compared with control levels, but a trend toward an increased expression after 24 h could be observed (Fig. 4E).

Exposure of HUVECs to perfusate (with 4 μg/ml TNF-α and 10 μg/ml melphalan) for 1 h resulted in
E-SELECTIN EXPRESSION

The induction and expression of cellular adhesion molecules and their relevance for leukocyte adhesion to endothelial cells have been well documented in vitro (23-26). Neutrophils, CD4+ lymphocytes, monocytes, eosinophils, and basophils also use VCAM-1 and ICAM-1. In vivo interactions, however, are more complex to interpret. Studies by Silver et al. (27), Cotran et al. (28), Mumm et al. (29,30), and Pober et al. (31,32) described the kinetics of expression of cellular adhesion molecules in natural disease processes in humans and after intra-

FIG. 5. Immunohistochemical analysis of the expression of adhesion molecules in biopsies of isolated limb perfusion-treated melanoma metastasis, A, C, Immunostaining for E-selectin on a frozen section of a melanoma metastasis, 40 min after perfusion with TNF-α and melphalan. B, D, Immunostaining for E-selectin on a frozen section of a melanoma metastasis, 40 min after perfusion with TNF-α and melphalan. A, and an adjacent section showing expression of ICAM-1. E, High-power images of the same sections as shown in A and B, complemented with a staining for a marked upregulation of E-selectin and ICAM-1.

FIG. 6. Immunohistochemical analysis of the expression of E-selectin in biopsies of isolated limb perfusion (ILP)-treated skin and sarcoma from one patient. A-B, E-selectin on a Frozen section of normal skin, 40 min after ILP with TNF-α and melphalan. A, Superficial layer, B, deep layer. C, Upper dermis. D, Lower dermis. E, High-power images of the same sections as shown in A and B, complemented with a staining for E-selectin in a serial section to C.

FIG. 4. Immunohistochemical analysis of the expression of E-selectin in biopsies of isolated limb perfusion (ILP)-treated skin and sarcoma from one patient. A-D, E-selectin on a Frozen section of normal skin, 40 min after ILP with TNF-α and melphalan. A, Superficial layer, B, deep layer. C, Upper dermis. D, Lower dermis. E, High-power images of the same sections as shown in A and B, complemented with a staining for E-selectin in a serial section to C.
In baboons, intradermal injections of TNF-α (or TNF-α with IFN-γ) induced a rapid induction of E-selectin expression on the vascular endothelium (which correlated with neutrophil extravasation) and a delayed increase in ICAM-1 (which correlated with the onset of lymphocyte accumulation). In humans, diseased tissues have been examined for the expression of cell-adhesion molecules. E-selectin was present on vascular endothelial cells in the acute inflamed skin (19,34) and on endothelial cells in several tumors characterized by high local concentrations of cytokines (especially TNF-α; 35). Intradermal injections of TNF-α indicate that TNF-α is pro-inflammatory in human skin and modulates cutaneous adhesion molecule expression (36).

A pharmacologically high dose of TNF-α is given in combination with melphalan during the ILP, a regimen that is likely to yield a different pathophysiologic response than is observed during an inflammatory reaction. Renard et al. (7) investigated biopsies of 27 patients (melanoma and sarcoma) treated with high doses of TNF-α, IFN-γ, and melphalan. The authors suggested that the clinically evident preferential sensitivity of the tumor vasculature for the triple-combination therapy could be based on a cascade starting with a selective overexpression of cellular-adhesion molecules by the tumor vascular endothelium. However, a comparison with unexposed and exposed skin from the same patients was not available.

In our study, we sequentially surveyed skin tissue with and without tumor lesions before and after ILP and TNF-α and melphalan, without IFN-γ. We found a marked immunostaining for E-selectin on the vascular endothelium 30 min after termination of perfusion in both normal skin and the melanoma and sarcoma lesions. The percentage of vascular endothelium that became positive for E-selectin was even higher in normal skin than in the tumors (both melanoma and sarcoma). Therefore, a selective overexpression of adhesion molecules on the tumor vasculature after perfusion cannot be the mechanism behind the antitumor effect. It is our opinion that the limited material in the “normal skin” group in the study of Renard et al. (9) may explain the different conclusion reached by these authors.

The rapid increase of E-selectin expression after ILP in both tumor and normal vessels makes this adhesion molecule not a useful marker to discriminate between “normal” and “tumor” vessels, but it may mark those vessels that were actually perfused. In this respect, it is notable that in both melanoma and sarcoma lesions expression of E-selectin was confined to the vascular endothelium in the periphery of the tumor. We therefore speculate that the agents used may not or have poorly reached the tumor center. According to Jain (37,38), aberrant branching and twisting of the vasculature and abnormal high pressure in the interstitial matrix of the tumor center may have contributed to this uneven distribution of the drugs.

We were surprised to find leukostasis and an inflammatory infiltrate in the biopsies of only one patient with melanoma. Expression of an inducible cell-adhesion molecule like E-selectin is apparently not necessarily followed by leukocyte adhesion. This phenomenon may be explained by assuming that the adhesion properties of leukocytes to E-selectin are also dependent on its ligand (39), which may be functionally inactive, as stated by Pober and Cotran (31). Alternatively, inhibitory factors may be present. For example, IL-8 renders neutrophils less able to interact with E-selectin (40), and increased levels of this cytokine (and IL-6) have been demonstrated in the ILP circuit during treatment (41). Soluble adhesion molecules, shed from the cell surface, may counteract leukocyte accumulation as well (42). The presence of these factors was not analyzed in our material. For an optimal monitoring of the duration of E-selectin expression and infiltrate formation in the sarcoma patients, the number of biopsies has to be extended at least to 8–12 h after perfusion. Obviously, this is limited by clinical and ethical restrictions based on the increased infection risk of taking needle biopsies.

The response rate in melanoma-in-transit metastasis after double-drug ILP (CR in six of seven patients) was comparable with results after triple-combination therapy. In contrast to earlier reports, we did not find hemorrhagic and coagulative necrosis in the melanoma lesions within 24 h after perfusion. Sampling bias was minimized by taking multiple biopsies per period per patient. In case of a complete response, biopsies 8 weeks after ILP revealed dermal fibrosis with infiltration by macrophages and lymphocytes. (Biopsies that were taken 8–10 weeks after perfusion are not included in Table 1. These biopsies were formalin-fixed and embedded in paraffin to verify the response to treatment but were not available for immunohistochemistry.)

The presence of regression of melanoma in the absence of granulocytes and hemorrhagic or coag-
ulative necrosis may imply that the proposed cas-

cade, starting with E-selectin expression, is not the
decisive mechanism resulting in regression of the
tumor observed in our melanoma patients. The ob-
served regression of the melanoma lesions 8–10
weeks after perfusion may still be immune medi-
ated, a possibility that needs future investigations.
The variability in response to ILP and the occur-
rence of necrosis may be a result of difference in the
extent of (neo)vascularization and tumor volume.
All the melanoma metastases we analyzed had a
diameter $\leq 0.5$ cm. Obviously, the sensitivity
of the tumor for ILP is influenced by more fac-
tors than the mere expression of adhesion mole-
cules. For instance, differences in the interstitial
environment and in immunoreactivity between tu-
mor and normal tissues may play a role. Further
investigations are therefore necessary to explain the
exact nature of this selective response.

Acknowledgment: This study was supported by a grant
from the Dutch Cancer Society (NKB 93-659). We thank
F. J. R. Rietveld for his expert technical assistance with
IEM.

REFERENCES


nografts treated with recombinant human tumor necrosis
factor alone or in combination with interferons. Cancer Res

2. Haranaka K, Satomi N, Sakurai A. Antitumor activity of
murine tumor necrosis factor (TNF) against transplanted
murine tumors and heterotransplanted human tumors in

human tumor necrosis factor administered as a 24 h intra-
venous infusion: a phase I and pharmacologic study. J Natl

4. Asher A, Mule JJ, Reichert CM, Shilone E, Rosenberg SA.
Studies on the anti-tumor efficacy of systemically adminis-
tered recombinant tumor necrosis factor against several mu-

Isolated perfusion of the limb with high-dose tumour necro-
sis factor-alpha (TNF-a), interferon-gamma (IFN-\(\gamma\)) and
melphalan for melanoma stage III: results of a multi-centre

for using TNF alpha and chemotherapy in regional therapy

7. Eggermont AMM, Liénard D, Scharffordt Koops H, Kroon
BBR, Rosenhaimer F, Lejeune FJ. Limb salvage by isolated
limb perfusion of the limbs with high dose TNF-a, gamma
interferon and melphalan for stage III melanoma and irre-
sectable soft tissue sarcomas of the extremities. In: Contri-
butions to oncology. Karger, in press.

8. Liénard D, Ewalenko P, Delmote JI, Renard N, Lejeune
FJ. High-dose recombinant tumor necrosis factor-alpha in
combination with interferon gamma and melphalan in iso-
lation perfusion of the limbs for melanoma and sarcoma. J Clin

9. Renard N, Liénard D, Lespagnard L, Eggermont AMM,
Heimann R, Lejeune FJ. Early endothelium activation and
polymorphonuclear cell invasion precede specific necrosis
of human melanoma and sarcoma treated by intravascular
high dose tumor necrosis factor-alpha (rTNF-a). Int J Cancer

and platelet aggregation in human melanoma after perfusion

terization of the anti-tumour activities of human tumour nec-
rosis factor-alpha and the comparison with other cytokines:
138:4023–32.

and intercellular adhesion molecule-1 are released by ac-
vitated human endothelial cells in vitro. Immunology 1992;77

13. World Health Organization. WHO handbook for reporting
results of cancer treatment. WHO Offset Publ No 48.

14. Ruitter DJ, Schlingemann RO, Rietveld FJR, et al. Monoclo-
ナル antibody defined human endothelial antigens as vascular

antibody PAL-E specific for endothelium. Lab Invest 1985;

of ICAM-1 expression in primary lesions and serum of patients

17. Leeuwenberg JEM, Jeunhomme TMA, Buurman WA. Role
of ELAM-1 in adhesion of monocytes to activated endo-

HW, Weber PC. Antioxidants inhibit monocyte adhesion by
suppressing nuclear factor-kappa B mobilization and induc-
tion of vascular adhesion molecule-1 in endothelial cells
stimulated to generate radicals. Arterioscler Thromb 1994;
14(10):1665–73.

19. Simmonds D, Needham L. Vascular endothelium: interac-
tions with circulating cells. Gordon: Elsevier Science Pub-

20. Bancroft DJ, Stevens A, eds. Theory and practice of histo-
logical techniques. New York: Churchill Livingstone,

Ruiter DJ, De Waal RMW. Accumulation of intercellular
adhesion molecule-1 in senile plaques in brain tissue of pa-
104–16.

22. Von Asmuth EUJ, Smeets EF, Ginsel LA, Onderwater JMJ,
Leeuwenberg JFM, Buurman WA. Evidence for endocyto-
sis of E-selectin in human endothelial cells. Eur J Immunol

23. Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS, Gim-
brone MA Jr. Identification of an inducible endothelial-
leucocyte adhesion molecule. Proc Natl Acad Sci USA
1987;84(24):9238–42.

24. Bevilacqua MP, Stengelin S, Gimbrone MA Jr, Seed B.
Endothelial leucocyte adhesion molecule I: an inducible recep-
tor for neutrophils related to complement regulatory pro-

25. Elies MJ, Osborn L, Takada Y, Crouse C, Luohowskyi S,
Hemler ME. VCAM-1 on activated endothelium interacts
with the leucocyte integrin VLA-4 at a site distinct from the

26. Westphal JR, De Waal RMW. The role of adhesion mole-

J Immunother, Vol. 19, No. 1, 1996
30. Munro JM, Pober JS, Cotran RS. Recruitment of neutrophils in local endotoxin response: association with de novo endothelial expression of endothelial leucocyte adhesion mole­